392 related articles for article (PubMed ID: 21232047)
1. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
2. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase 4 inhibitors for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs.
Mulhall AM; Droege CA; Ernst NE; Panos RJ; Zafar MA
Expert Opin Investig Drugs; 2015; 24(12):1597-611. PubMed ID: 26419847
[TBL] [Abstract][Full Text] [Related]
5. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast : the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD.
Tashkin DP
Expert Opin Pharmacother; 2014 Jan; 15(1):85-96. PubMed ID: 24032576
[TBL] [Abstract][Full Text] [Related]
7. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast for COPD.
Izquierdo JL; Aparicio J
Drugs Today (Barc); 2010 Nov; 46(11):823-31. PubMed ID: 21225021
[TBL] [Abstract][Full Text] [Related]
9. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
10. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of roflumilast in the COPD frequent exacerbator phenotype.
Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA
Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188
[TBL] [Abstract][Full Text] [Related]
12. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic evaluation of roflumilast.
Lahu G; Nassr N; Hünnemeyer A
Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1577-91. PubMed ID: 22059647
[TBL] [Abstract][Full Text] [Related]
14. Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD.
Giembycz MA; Field SK
Drug Des Devel Ther; 2010 Jul; 4():147-58. PubMed ID: 20689641
[TBL] [Abstract][Full Text] [Related]
15. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H
Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416
[TBL] [Abstract][Full Text] [Related]
16. [Roflumilast: clinical review of a new option for the treatment of inflammation in COPD].
Martínez FJ
Arch Bronconeumol; 2010 Nov; 46 Suppl 9():8-11. PubMed ID: 21320811
[No Abstract] [Full Text] [Related]
17. Roflumilast: doubtful efficacy but clear harms in COPD.
Prescrire Int; 2013 Jan; 22(134):5-9. PubMed ID: 23367674
[TBL] [Abstract][Full Text] [Related]
18. New therapeutic options in the management of COPD - focus on roflumilast.
Antoniu SA
Int J Chron Obstruct Pulmon Dis; 2011; 6():147-55. PubMed ID: 21468165
[TBL] [Abstract][Full Text] [Related]
19. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD.
Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ
Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339
[TBL] [Abstract][Full Text] [Related]
20. [Phosphodiesterase-4 inhibitors: a new target in treatment of COPD].
Michels G; Erdmann E; Pfister R
Dtsch Med Wochenschr; 2011 Nov; 136(44):2267-70. PubMed ID: 22028292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]